Epitalon + Pinealon (Khavinson Bioregulator Stack)

Epitalon, Pinealon, and Thymalin all come from the Khavinson peptide bioregulator catalog, a program started in the 1970s at what became the St. Petersburg Institute of Bioregulation and Gerontology. Its central idea is that short peptides, each linked to a particular organ, can restore that organ's age-related decline. Combining several tissue-targeted peptides in short, repeated courses is built into the tradition, so stacks like this one follow the program's own logic. Our Khavinson Bioregulators family page covers the whole catalog, its history, and the contested gene-regulation hypothesis behind it. Epitalon (also spelled Epithalon) is a synthetic tetrapeptide, Ala-Glu-Asp-Gly. The Khavinson group derived it from Epithalamin, an older peptide extract of animal pineal glands. Its claimed effects are activating telomerase and lengthening telomeres in human cells (Khavinson et al., Bull Exp Biol Med 2003), and restoring the night-time melatonin rhythm that flattens with age. Those claims make it the most-searched Khavinson peptide in Western longevity circles. Pinealon is a synthetic tripeptide, Glu-Asp-Arg. Despite its name, its published work is mostly about neurons rather than the pineal gland. That work covers protection from oxidative stress and hypoxia in rodent brain and in cerebellar and PC12 cell cultures. In the one study that tested both peptides side by side in rat pineal-gland cultures (Khavinson et al., Bull Exp Biol Med 2011), only Epitalon stimulated pinealocyte proliferation and secretory markers. Pinealon did not. So the pairing is better understood as pineal plus brain than as two pineal peptides doubling up. Thymalin is a peptide complex extracted from calf thymus. It has been used in Russian clinical practice since the late 1970s as an immune modulator for older and immunocompromised patients. It enters this stack, and the common search "epitalon and thymalin," through the program's flagship human study. That study gave Thymalin and Epithalamin to elderly people in St. Petersburg and Kyiv and reported lower mortality over 6–8 years (Khavinson & Morozov, Neuro Endocrinol Lett 2003). The program also proposes a pineal–thymus axis: Khavinson-lineage reviews describe the pineal gland and thymus shrinking together with age and argue that pineal peptides slow thymic involution. The stack, then, is the Khavinson neuroendocrine–immune idea in miniature: Epitalon for the pineal gland and circadian system, Pinealon for neurons, and Thymalin for immune aging, run together in periodic courses. People search for it as a protocol or as a pre-mixed blend. The honest answer is that this logic comes from one research tradition and has not been tested independently.

The Khavinson framework proposes one mechanism for all its short peptides. They are said to cross cell and nuclear membranes, bind specific DNA sequences or histone proteins, and switch on tissue-typical gene expression that declines with age. Each component's proposed synergy rests on that mechanism. It has been described in the group's own papers, including in-vitro peptide–DNA binding and fluorescence studies. It has not been confirmed with the structural biology, such as crystallography or cryo-EM of peptide–DNA complexes, that mainstream molecular biology would require for sequence-specific gene regulation by a three- or four-amino-acid peptide. Within that framework, the components divide the work. Epitalon is proposed to restore pinealocyte function, the night-time melatonin peak, and telomerase activity. Pinealon is proposed to raise antioxidant and anti-apoptotic gene expression in neurons, with reported effects on ERK1/2 signaling and reactive oxygen species. Thymalin and its dipeptide fractions (Glu-Trp and Lys-Glu) are proposed to support T-cell maturation and thymic function. The link between them is pineal–thymus cross-talk. Melatonin and pineal peptides are proposed to slow thymic involution, and thymic peptides to support pineal function. A Khavinson-lineage review concluded that the pineal-to-thymus effect is the stronger direction. The synergy is entirely theoretical. No study has given Epitalon and Pinealon together, with or without Thymalin, and measured anything. The only direct comparison, in the 2011 pineal-culture study, shows the two synthetic peptides doing different things in the same tissue. That fits the idea of different targets, but says nothing about whether they add up. Basic pharmacology adds a further question. Tri- and tetrapeptides are cleared from blood in minutes and broken down quickly by peptidases. Whether enough intact peptide reaches the pineal gland, neurons, or thymus, especially from oral or sublingual products, has never been measured with independent pharmacokinetic studies.

The evidence for this stack is weak, and it is concentrated in one research lineage to an unusual degree. The core papers come from Khavinson's institute in St. Petersburg and a tight network of collaborators, including Vladimir Anisimov's group at the N.N. Petrov oncology institute and Oleg Korkushko's group at the Institute of Gerontology in Kyiv. Most appear in Russian-language or low-impact journals, and many do not report randomization, blinding, or allocation methods. Khavinson died in January 2024. Independent replication outside this network is close to nonexistent. The flagship human data come from Khavinson & Morozov (Neuro Endocrinol Lett 2003). They followed 266 elderly people for 6–8 years, with peptide courses given during the first 2–3 years. Compared with controls, they reported 2.0–2.1-fold lower mortality with Thymalin, 1.6–1.8-fold lower with Epithalamin, and 2.5-fold lower with the two combined. A separate group treated with both every year for 6 years had 4.1-fold lower mortality. Four caveats matter. First, these were gland extracts (Thymalin from thymus, Epithalamin from pineal tissue), not the synthetic Epitalon and Pinealon sold today. Results from extracts do not transfer automatically to a defined synthetic tetrapeptide. Second, the abstract does not describe how participants were assigned, whether anyone was blinded, or how large each group was. Third, the same cohort was published in Russian in 2002 (Adv Gerontol). It is one study, not two. Fourth, the effect sizes are far larger than any validated intervention has achieved in older adults, which calls for replication before anyone relies on them. Other human data come from the same network and are small. Korkushko's Kyiv group gave Epithalamin to elderly patients with coronary disease and accelerated cardiovascular aging, and reported 28% fewer deaths after 12 years (Bull Exp Biol Med 2006). A 2011 15-year follow-up from the same authors, apparently of the same cohort, describes only 39 treated patients and 40 controls, with 6 courses given over 3 years. A Russian-language 2007 paper reported that both Epithalamin and synthetic Epitalon restored the night-time melatonin rise in old monkeys and elderly people. That is the closest thing to human data for synthetic Epitalon on the sleep angle, but it is small and unreplicated. Pinealon's human evidence is an occupational study in long-haul truck drivers (Bashkireva, Adv Gerontol 2012). It reported better psycho-emotional scores with bioregulator peptides, and the best result came from Pinealon combined with Vesugen, a vascular peptide, not with Epitalon. The preclinical picture is mixed. Epitalon's telomerase activation in human fibroblasts (Khavinson 2003) remained a single-lab finding until 2025. That year a Brunel University London group (Al-Dulaimi et al., Biogerontology 2025) independently confirmed dose-dependent telomere lengthening in normal human cells through hTERT and telomerase. The same study found that in two breast-cancer cell lines Epitalon lengthened telomeres by activating Alternative Lengthening of Telomeres (ALT), a cancer-associated mechanism. The first independent replication therefore also produced the first independent cancer-relevant warning sign. Pinealon's preclinical record is cell-culture antioxidant and anti-apoptotic effects plus rodent hypoxia models, all from the same network. To summarize: no trial of synthetic Epitalon plus Pinealon, with or without Thymalin, exists. The stack's human evidence is borrowed from extract studies of uncertain design that were never replicated, and its mechanism has not been confirmed by standard structural or pharmacokinetic methods.

No clinically validated protocol exists for this stack. What follows reflects patterns commonly discussed in Khavinson-tradition and longevity communities. It is not a recommendation. Anyone considering these peptides should do so under the supervision of a clinician, with age-appropriate cancer screening up to date first, because Epitalon's proposed mechanism is telomerase activation. The Khavinson tradition uses courses, not continuous dosing. Peptides are given daily for a short block, typically 10–20 days, then stopped for months. Courses are repeated once or twice a year. Running these peptides every day indefinitely is not part of the published tradition. Epitalon: forum-described protocols most often use 5–10 mg per dose subcutaneously, daily for 10–20 days, repeated about every 6 months. Khavinson-group human studies used intranasal and intramuscular routes at total doses in the low-milligram range per course. Because no independent dose-finding trial exists, these numbers reflect convention. Pinealon: injectable research-chemical protocols commonly describe 100–200 mcg per dose. Russian Khavinson-affiliated capsule and sublingual products deliver low-milligram amounts and are sold as dietary peptide complexes. Courses typically run 10–30 days, repeated every 3–6 months. Whether oral or sublingual Pinealon is absorbed intact has not been independently measured. Thymalin (optional third component): Russian clinical protocols use 5–30 mg by intramuscular injection daily for 5–10 days, repeated every 3–6 months. Research-chemical protocols often cite 10 mg/day. The extract is heterogeneous, so "Thymalin" from different sources may not have the same composition. Doses from the 2003 mortality study cannot be applied to synthetic peptides. When stacked, the components are usually run in the same course window, for example a 10-day block in spring and autumn. Pre-mixed "Epitalon/Pinealon" blends fix the ratio and make it hard to verify that each peptide is actually present. Separate, third-party-tested components are the more verifiable route. Track sleep timing and quality from baseline (a wearable or a simple sleep diary) if circadian effects are the goal. Expect the honest outcome of a single course to be hard to tell apart from placebo.